| C Scott Taylor, MD | |
|
3723 W 12600 S, Suite 270, Riverton, UT 84065-7295 | |
| (801) 285-4640 | |
| Not Available |
| Full Name | C Scott Taylor |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 24 Years |
| Location | 3723 W 12600 S, Riverton, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508811167 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 6108210-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverton Hospital | Riverton, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
In a recent study, researchers explore strategies for managing pandemics as well as model potentially optimal solutions.
The Substance Abuse and Mental Health Services Administration (SAMHSA) announced it is awarding up to $53.4 million in new State Incentive Grants for up to five years. These grants are used by states or tribes to implement a strategic approach in communities across the state for substance abuse prevention.
Intracerebral hemorrhage is a type of stroke that affects two million people worldwide each year. Despite its seriousness, no effective treatment has yet been developed. But if a recent study in the journal Nanomedicine is right, good news for doctors and patients might one day arrive in a very small package: namely, a "peptide nanofiber scaffold."
Stroke risk factors such as high blood pressure, diabetes, heart disease and smoking are common and on the rise among Native Americans with clot-caused stroke, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.
› Verified 8 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
In a recent study, researchers explore strategies for managing pandemics as well as model potentially optimal solutions.
The Substance Abuse and Mental Health Services Administration (SAMHSA) announced it is awarding up to $53.4 million in new State Incentive Grants for up to five years. These grants are used by states or tribes to implement a strategic approach in communities across the state for substance abuse prevention.
Intracerebral hemorrhage is a type of stroke that affects two million people worldwide each year. Despite its seriousness, no effective treatment has yet been developed. But if a recent study in the journal Nanomedicine is right, good news for doctors and patients might one day arrive in a very small package: namely, a "peptide nanofiber scaffold."
Stroke risk factors such as high blood pressure, diabetes, heart disease and smoking are common and on the rise among Native Americans with clot-caused stroke, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| C Scott Taylor, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (801) 651-8695 | C Scott Taylor, MD 3723 W 12600 S, Suite 270, Riverton, UT 84065-7295 Ph: (801) 285-4640 |
News Archive
In a recent study, researchers explore strategies for managing pandemics as well as model potentially optimal solutions.
The Substance Abuse and Mental Health Services Administration (SAMHSA) announced it is awarding up to $53.4 million in new State Incentive Grants for up to five years. These grants are used by states or tribes to implement a strategic approach in communities across the state for substance abuse prevention.
Intracerebral hemorrhage is a type of stroke that affects two million people worldwide each year. Despite its seriousness, no effective treatment has yet been developed. But if a recent study in the journal Nanomedicine is right, good news for doctors and patients might one day arrive in a very small package: namely, a "peptide nanofiber scaffold."
Stroke risk factors such as high blood pressure, diabetes, heart disease and smoking are common and on the rise among Native Americans with clot-caused stroke, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.
› Verified 8 days ago